



RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

May 26, 2016

To

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051.

The Manager
Listing Department
BSE Limited
Corporate Relationship Department
25, P.J. Towers,
Dalal Street,
Mumbai 400 001.

Dear Sirs,

Sub: Outcome of Board Meeting
(Scrip Code: RPGLIFE / 532983)

This is to inform you that the Board of Directors of the Company at its meeting held on May 26, 2016, has approved the sale and transfer of its Biotech Unit located at 2702/A and 2702/P, GIDC, Ankleshwar, Gujarat as a going concern on a slump sale basis to M/s Intas Pharmaceuticals Limited.

A Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed.

Kindly take the same on records.

Thanking you

Yours faithfully
For **RPG Life Sciences Limited**


Rajesh Shirambekar
Head – Legal and Company Secretary



Encl: as above




RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

DISCLOSURE UNDER REGULATION 30 OF THE LISTING REGULATIONS

Sale or disposal of unit or division or subsidiary of the listed entity:

Sr.	Particulars	Details			
		Sr.	Particulars	Networth (Rs. In lakhs)	Income from operations (Rs. In lakhs)
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	1	RPGLS	133.59	279.32
		2	Biotech	17.55	24.13
		3	Percentage	13.13%	8.63%
2	Date on which agreement for sale has been entered into	May 26, 2016			
3	The expected date of completion of sale/disposal	August 31, 2016			
4	Consideration received from such sale/disposal	Rs.25 crores (Rupees Twenty Five crore only)			
5	Brief details of the Buyers and whether any of the Buyers belong to the promoter/promoter group/group companies. If yes, details thereof	M/s Intas Pharmaceuticals Limited ("the Buyer") is a Company engaged in the business of development, manufacturing and marketing of pharmaceutical products. The Buyer does not belong to Promoters or Promoter Group of the Seller.			
6	Name of the entities. Details in brief such as size, turnover etc.	The Seller - RPG Life Sciences Limited The Buyer - Intas Pharmaceuticals Limited The details of the Buyer and the Seller and information such as size, turnover etc. is available on respective Company's website viz. www.rpglifesciences.com and www.intaspharma.com .			



Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127
E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com
CIN : L24232MH2007PLC169354





RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

7	Whether transaction would fall under related party transaction? If yes, whether the same is done at arms' length	No
8	Area of the business of the entity	The Buyer and the Seller are engaged in the business of manufacturing and marketing of pharmaceutical products.
9	Rationale for proposed Slump Sale	In order to strengthen the focus on core areas of business and to improve long term competitiveness in a rapidly changing Pharmaceutical market by aligning with the management framework and strategy, it was imperative to sale off the Biotech Unit as a going concern on slump sale basis.
10	In case of cash consideration amount or otherwise share entitlement/merger; brief details of change in shareholding pattern (if any) of listed entity	Cash consideration of Rs.25 crore (Rupees Twenty Five crores only) No change in shareholding pattern of the Seller.

